## Clinical Presentation Analysis This patient presents with **rapidly progressive glomerulonephritis (RPGN)** with features suggestive of **membranoproliferative glomerulonephritis (MPGN) or C3 glomerulonephritis**: ### Key Diagnostic Clues 1. **Acute nephritic syndrome** — haematuria, hypertension, oedema, RBC casts 2. **Rapidly declining renal function** — Cr 0.9 → 2.8 mg/dL in days to weeks 3. **C3 deposition pattern** — marked C3 reduction (8 mg/dL) is hallmark of: - Membranoproliferative GN (MPGN) - C3 glomerulonephritis (C3GN) - Post-infectious GN (less likely given rapid progression) 4. **Negative serologies** — rules out lupus, ANCA-associated vasculitis, anti-GBM disease 5. **Normal kidney size** — excludes chronic kidney disease; acute process ## Why Renal Biopsy is Essential **High-Yield:** In RPGN with C3 deposition and negative serologies, **renal biopsy is mandatory** to: 1. **Confirm diagnosis** — differentiate MPGN from C3GN from other patterns 2. **Assess for crescents** — presence/absence determines prognosis and treatment intensity 3. **Guide immunosuppression** — biopsy findings determine whether to use steroids ± cyclophosphamide vs. alternative agents 4. **Establish baseline** — allows comparison if repeat biopsy needed **Key Point:** Biopsy should be performed **urgently** (within 1–2 weeks) because: - Rapidly progressive disease may progress to end-stage renal disease - Early immunosuppression guided by biopsy improves outcomes - Delay risks irreversible renal damage ## Management Algorithm ```mermaid flowchart TD A[RPGN + C3 deposition + Negative serology]:::outcome --> B[Urgent renal biopsy]:::action B --> C{Biopsy findings?}:::decision C -->|Crescents present| D[High-dose steroids + cyclophosphamide]:::action C -->|No crescents, MPGN pattern| E[Corticosteroids ± additional agents]:::action C -->|C3GN pattern| F[Corticosteroids; consider C5 inhibitor if severe]:::action D --> G[Monitor Cr, proteinuria weekly]:::action E --> G F --> G ``` ## Why NOT Other Options? ### Option 1: High-dose steroids without biopsy - **Trap:** Starting immunosuppression before biopsy diagnosis is suboptimal - Biopsy findings determine whether additional agents (cyclophosphamide) are needed - Steroids alone may be insufficient for crescentic disease - Delaying biopsy risks irreversible renal damage ### Option 2: Plasma exchange immediately - **Trap:** Plasma exchange is NOT indicated for MPGN or C3GN - PE is reserved for: - Anti-GBM disease (negative here) - ANCA-associated vasculitis with pulmonary haemorrhage (ANCA negative here) - Thrombotic microangiopathies (no clinical evidence) - Premature PE exposes patient to unnecessary morbidity ### Option 3: ACE inhibitor monotherapy - **Trap:** Monotherapy is inadequate for RPGN - ACE inhibitors provide renal protection but do NOT arrest rapidly progressive disease - Waiting 4 weeks risks progression to ESRD - This approach is appropriate only for stable, non-progressive GN ## Clinical Pearl The **marked C3 reduction (8 mg/dL)** is the diagnostic linchpin. Combined with: - Rapid renal decline - Negative serologies (ANA, ANCA, anti-GBM) - Acute nephritic picture This pattern strongly suggests **C3-mediated GN** (MPGN or C3GN), which requires biopsy for precise classification and to assess crescentic involvement. Treatment intensity depends on biopsy findings. ## Post-Biopsy Management **If crescents present (>50%):** - High-dose IV methylprednisolone 500 mg daily × 3 days, then oral prednisolone 1 mg/kg/day - Cyclophosphamide 0.5–1 g/m² IV monthly × 6 months OR oral daily **If no crescents (MPGN/C3GN pattern):** - Oral prednisolone 0.5–1 mg/kg/day - Consider additional agents (mycophenolate, C5 inhibitor) based on response
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.